[Efficacy of moxonidine, an imidazoline receptor agonist, in patients with essential hypertension].
OBJECTIVE
Study of zint (moxonidine), a hypotensive drug with the central mechanism of action.


METHODS
The hemodynamics and platelet functional activity were assessed in 30 patients with essential hypertension treated by zint in a daily dose of 0.4 mg, taken in the morning, for 3 months.


RESULTS
By the end of treatment the systolic arterial pressure decreased by 23 +/- 4 mm Hg, diastolic by 15 +/- mm Hg, mean pressure by 17 +/- 2 mm Hg, and heart rate by 5 +/- 4 str/min. Echography showed that myocardial hypertrophy decreased but negligibly. An evident decrease of ADP-induced platelet aggregation was observed.


CONCLUSIONS
Zint therapy may be a most physiological method of arterial hypertension control.
Baliakina
E V
EV
Patrusheva
I F
IF
Rynskova
E E
EE
Iurenev
A P
AP
D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004452:Echocardiography; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging / Q000188:drug therapy; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D054755:Imidazoline Receptors; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011955:Receptors, Drug / Q000819:agonists*; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D007093:Imidazoles; D054755:Imidazoline Receptors; D010975:Platelet Aggregation Inhibitors; D011955:Receptors, Drug; C043482:moxonidine
Opyt primeneniia agonista imidazolinovykh retseptorov moksonidina u bol'nykh gipertonicheskoĭ bolezn'iu (sobstvennoe nabliudenie).